Valuation
- Market cap
- 2,540,000
- Revenue TTM
- $0
- Net income TTM
- $-11,630,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 3,999,700
- Avg volume
- 6,317,292
- Day's range
- $0.28 – $0.41
- Shares out
- 8,190,000
- Stochastic %K
- 7%
- Beta
- 2.21
- Analysts
- —
- Price target
- —
Company profile
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowe...
Show more
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
- Industry
- Computer Hardware
- Sector
- Technology
- Phone
- 856 848 8698
- Website
- https://www.qctechnologies.com
- Address
- 1185 Avenue of the Americas, Suite 249, New York, United States
Latest news
No headlines yet.
Stocktwits
Merlintrader
Nov 16, 8:15 PM
$QCLS | NEWS – Nov 16
Q/C Technologies ends Q3 with over 10 million dollars for optical processor development. The company expects initial OPU device designs before year-end 2026 and a hardware demonstration in 2027.
Source: Q/C Technologies press release (GlobeNewswire), Nov 16, 2026.
Not investment advice.
Details and primary sources in our
$QCLS stock hub:
https://www.merlintrader.com/qc-technologies-qcls-stock-hub/
0 replies
Stormra
Nov 16, 3:09 PM
$QCLS They were given a 180 day extension.
0 replies
d_risk
Nov 16, 3:03 PM
$QCLS - Q/C TECHNOLOGIES, INC. - 10Q - Updated Risk Factors
Five consecutive trading days of suspension or loss of eligible listing could let preferred holders demand cash redemption. Series H conversion could substantially dilute common holders.
#riskfactors #secfilings
🟢 Added 🟠 Removed
https://d-risk.ai/QCLS?filing=PvGp5dm1Zq2Ab4nzh99AI
1 replies
focafoca99
Nov 16, 2:41 PM
$QCLS introducing over
$10M in cash and marketable securities to fund its optical processing unit development. https://www.rapidticker.com/news/qcls-qc-technologies-reports-over-10-abde0c
0 replies
RobbysInvestmentLLC
Nov 16, 2:18 PM
0 replies